WO2001036456A3 - Chlamydia antigens and corresponding dna fragments and uses thereof - Google Patents

Chlamydia antigens and corresponding dna fragments and uses thereof Download PDF

Info

Publication number
WO2001036456A3
WO2001036456A3 PCT/CA2000/001345 CA0001345W WO0136456A3 WO 2001036456 A3 WO2001036456 A3 WO 2001036456A3 CA 0001345 W CA0001345 W CA 0001345W WO 0136456 A3 WO0136456 A3 WO 0136456A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna fragments
corresponding dna
chlamydia
chlamydia antigens
strain
Prior art date
Application number
PCT/CA2000/001345
Other languages
French (fr)
Other versions
WO2001036456A2 (en
Inventor
Andrew D Murdin
Raymond P Oomen
Joe Wang
Pamela Dunn
Original Assignee
Aventis Pasteur
Andrew D Murdin
Raymond P Oomen
Joe Wang
Pamela Dunn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, Andrew D Murdin, Raymond P Oomen, Joe Wang, Pamela Dunn filed Critical Aventis Pasteur
Priority to AU13756/01A priority Critical patent/AU1375601A/en
Publication of WO2001036456A2 publication Critical patent/WO2001036456A2/en
Publication of WO2001036456A3 publication Critical patent/WO2001036456A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding an OppB gene product of a strain of Chlamydia pneumoniae and a promoter to effect expression of the OppB gene product in the host. Modifications are possible within the scope of this invention.
PCT/CA2000/001345 1999-11-15 2000-11-10 Chlamydia antigens and corresponding dna fragments and uses thereof WO2001036456A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13756/01A AU1375601A (en) 1999-11-15 2000-11-10 Chlamydia antigens and corresponding DNA fragments and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16491899P 1999-11-15 1999-11-15
US60/164,918 1999-11-15

Publications (2)

Publication Number Publication Date
WO2001036456A2 WO2001036456A2 (en) 2001-05-25
WO2001036456A3 true WO2001036456A3 (en) 2001-10-04

Family

ID=22596648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001345 WO2001036456A2 (en) 1999-11-15 2000-11-10 Chlamydia antigens and corresponding dna fragments and uses thereof

Country Status (2)

Country Link
AU (1) AU1375601A (en)
WO (1) WO2001036456A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO2000011181A1 (en) * 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
WO2000024901A1 (en) * 1998-10-28 2000-05-04 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000024902A1 (en) * 1998-10-28 2000-05-04 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000055326A1 (en) * 1999-03-12 2000-09-21 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001002575A1 (en) * 1999-06-30 2001-01-11 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO2000011181A1 (en) * 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
WO2000024901A1 (en) * 1998-10-28 2000-05-04 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000024902A1 (en) * 1998-10-28 2000-05-04 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000055326A1 (en) * 1999-03-12 2000-09-21 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001002575A1 (en) * 1999-06-30 2001-01-11 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISSPROT 1 January 1900 (1900-01-01), PEREGO M, ET AL: "OLIGOPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN OPPB", XP002166137, Database accession no. P24138 *
DONG-JI ZHANG ET AL: "Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.", INFECTION AND IMMUNITY, vol. 68, no. 6, June 2000 (2000-06-01), pages 3074 - 3078, XP002164567, ISSN: 0019-9567 *
KALMAN S ET AL: "COMPARATIVE GENOMES OF CHLAMYDIA PNEUMONIAE AND C. TRACHOMATIS", NATURE GENETICS,US,NEW YORK, NY, vol. 21, no. 4, April 1999 (1999-04-01), pages 385 - 389, XP000853883, ISSN: 1061-4036 *
MURDIN ANDREW D ET AL: "Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection.", JOURNAL OF INFECTIOUS DISEASES, vol. 181, no. Supplement 3, June 2000 (2000-06-01), pages S544 - S551, XP000997839, ISSN: 0022-1899 *
PEREZ MELGOSA M ET AL: "OUTER MEMBRANE COMPLEX PROTEINS OF CHLAMYDIA PNEUMONIAE", FEMS MICROBIOLOGY LETTERS,NL,AMSTERDAM, vol. 112, no. 2, 1 September 1993 (1993-09-01), pages 199 - 204, XP002057607, ISSN: 0378-1097 *
READ T D ET AL: "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39.", NUCLEIC ACIDS RESEARCH, vol. 28, no. 6, 15 March 2000 (2000-03-15), pages 1397 - 1406, XP002164566, ISSN: 0305-1048 *
RUDNER ET AL: "THE spo0K LOCUS OF BACILLUS SUBTILIS IS HOMOLOGOUS TO THE OLIGOPEPTIDE PERMEASE LOCUS AND IS REQUIRED FOR SPORULATION AND COMPETENCE", JOURNAL OF BACTERIOLOGY,US,WASHINGTON, DC, vol. 173, no. 4, 1 February 1991 (1991-02-01), pages 1388 - 1398, XP002092576, ISSN: 0021-9193 *
SHIRAI MUTSUNORI ET AL: "Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA.", NUCLEIC ACIDS RESEARCH, vol. 28, no. 12, 15 June 2000 (2000-06-15), pages 2311 - 2314, XP002166059, ISSN: 0305-1048 *
STEPHENS RS ET AL: "Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis [see comments]", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 282, no. 5389, 23 October 1998 (1998-10-23), pages 754 - 759, XP002104802, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
WO2001036456A2 (en) 2001-05-25
AU1375601A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
WO2001046224A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000066739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
IL161769A0 (en) Anbtimicrobial polypeptides from pseudoplectania nigrella
WO2001070174A3 (en) Vegf-modulated genes and methods employing them
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001075111A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE348892T1 (en) CHLAMYDIA ANTIGENS, CORRESPONDING DNA FRAGMENTS AND THEIR USES
WO2001075113A3 (en) Chlamydia myosin heavy chain homolog as antigen, corresponding dna fragments and uses thereof
WO2001074863A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001075112A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
WO1998018932A3 (en) Novel pesticidal toxins and nucleotide sequences which encode these toxins
WO2001075114A3 (en) Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof
EP2172214A3 (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000006742A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000026239A3 (en) $i(chlamydia) antigens and corresponding dna fragments and uses thereof
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
MXPA01004353A (en) Chlamydia.
WO1999051745A3 (en) Dna immunization against chlamydia infection
WO2000011183A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001036456A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001036455A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000006743A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000026237A3 (en) Chlamydia 98kd putative outer membrane protein and corresponding dna fragments and uses thereof
WO2000006739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase